Cagrilintide: Amylin Analog for Weight Management

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk, currently in advanced clinical development for obesity and type 2 diabetes management. While the GLP-1 receptor agonist class has dominated obesity medicine, cagrilintide targets a distinct but complementary pathway — the amylin system — offering additional appetite suppression that, when combined with semaglutide, produces weight loss approaching 22-25% in clinical trials. The combination product CagriSema (cagrilintide plus semaglutide) represents one of the most promising combination therapies in development for metabolic disease.

The Amylin System

Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to meals. It acts on the area postrema and nucleus tractus solitarius in the brainstem to produce satiety signaling distinct from GLP-1 pathways. Amylin reduces meal size and duration, slows gastric emptying, suppresses glucagon secretion, and helps regulate post-meal glucose excursions. Native amylin has a very short half-life and forms amyloid aggregates at higher concentrations — the basis for the amyloid plaques in pancreatic tissue in type 2 diabetes. Pramlintide, a short-acting amylin analog, has been approved since 2005 for adjunct diabetes management but requires multiple daily injections and has modest weight effects.

Cagrilintide's Pharmacological Advances

Cagrilintide (INN) solves amylin's pharmacological limitations through molecular engineering. By modifying the amylin molecule to prevent amyloid fibril formation, extending the fatty acid chain for albumin binding (like semaglutide), and optimizing receptor selectivity for amylin receptors (which are complexes of the calcitonin receptor with receptor activity-modifying proteins), cagrilintide achieves once-weekly subcutaneous dosing with stable, non-aggregating pharmacokinetics. This makes it practical for chronic obesity management in a way that native amylin and pramlintide are not.

Clinical Trial Results

In Phase 2 trials, cagrilintide monotherapy at 2.4 mg weekly produced approximately 10.8% weight loss over 26 weeks — meaningful but below the GLP-1 agonist class. The key finding was its complementary action with semaglutide. The CagriSema combination (cagrilintide 2.4 mg plus semaglutide 2.4 mg weekly) produced weight loss of approximately 17.1% over 32 weeks in Phase 2 — substantially more than either agent alone. Phase 3 trials (REDEFINE program) are examining CagriSema against semaglutide alone and placebo, with results expected to demonstrate the additive benefit of dual amylin/GLP-1 agonism. Early Phase 3 data has shown weight loss of 22-25% in some analyses.

Mechanism of Combination Benefit

The complementary weight loss from combining amylin and GLP-1 agonism reflects the distinct neural circuits engaged by each. GLP-1 receptors are concentrated in the hypothalamus and brainstem neurons projecting to food reward circuitry. Amylin receptors are concentrated in the area postrema and the lateral parabrachial nucleus — a brainstem hub that integrates meal termination signals. The two pathways converge on overlapping output circuits but are independently regulated, allowing additive suppression when both are activated simultaneously. This is analogous to combining two different analgesic mechanisms for pain: the combined effect exceeds either alone.

Comparison to Other Weight Loss Peptides

Positioned against the triple agonist retatrutide (GLP-1/GIP/glucagon, 24% weight loss) and dual agonist tirzepatide (GLP-1/GIP, 20-22%), CagriSema at 22-25% is competitive with the most effective available compounds. Each approach has different side effect considerations: retatrutide's glucagon component raises heart rate; CagriSema's amylin component may modulate calcium signaling through calcitonin receptor cross-talk. The amylin mechanism also has potential applications for type 1 diabetes management, where beta cells that produce both insulin and amylin are lost.

Regulatory Timeline and Availability

CagriSema is expected to submit for FDA approval in the 2026 timeframe if Phase 3 results confirm Phase 2 findings. Cagrilintide monotherapy may also pursue a separate regulatory pathway. Given Novo Nordisk's manufacturing infrastructure from semaglutide, supply constraints may be less severe than the initial Ozempic/Wegovy shortages, though high demand is anticipated.

FAQ

How does cagrilintide differ from pramlintide? Pramlintide requires multiple daily injections before meals and has modest weight effects (typically 2-3 kg). Cagrilintide is once-weekly and produces substantially greater weight loss (10.8% as monotherapy) through its optimized pharmacokinetics. Pramlintide is also prone to hypoglycemia risk when combined with insulin, while cagrilintide is designed for more stable glucose-independent effects.

Does cagrilintide have any cognitive benefits? Amylin receptors are present in brain regions involved in memory and cognition, and amylin analogs have shown some neuroprotective effects in Alzheimer's animal models. Whether cagrilintide translates these animal findings to clinical cognitive benefits is unknown and not a primary focus of current trials, but it represents an interesting area for future research.

Who is the ideal candidate for CagriSema? Individuals with obesity (BMI 30+ or 27+ with comorbidities) who seek maximum weight loss and have not achieved sufficient results with GLP-1 monotherapy are the primary target. Those with type 2 diabetes and obesity also stand to benefit from the dual glucose-lowering and weight reduction effects. The combination is not appropriate for those with thyroid C-cell tumor history or active pancreatitis.

Track your supplements in Optimize.